RWD ‘Fitness’ Steps for Pharma


How FDA’s new guidance on real-world data reshapes critical “fit-for-purpose” evaluations

Matthew W. Reynolds, vice president, real-world solutions, at IQVIA, dives into the implications of FDA’s recent draft guidance on using real-world data from electronic health records and medical claims data to aid in drug development and regulatory decision-making—and shares specific steps pharma companies can take to assess the relevance and quality of their data in light of this guidance.

The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.